Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor
Open Access
- 23 August 2018
- journal article
- research article
- Published by Bioscientifica in Endocrinology, Diabetes & Metabolism Case Reports
- Vol. 2018 (1)
Abstract
Summary: Adrenocortical carcinoma (ACC) during childhood is a rare malignant tumor that frequently results in glucocorticoid and/or androgen excess. When there are signs of microscopic or macroscopic residual disease, adjuvant therapy is recommended with mitotane, an adrenolytic and cytotoxic drug. In addition to the anticipated side effect of adrenal insufficiency, mitotane is known to cause gynecomastia and hypothyroidism in adults. It has never been reported to cause precocious puberty. A 4-year-old girl presented with a 6-week history of virilization and elevated androgen levels and 1-year advancement in bone age. Imaging revealed a right adrenal mass, which was subsequently surgically excised. Histology revealed ACC with multiple unfavorable features, including high mitotic index, capsular invasion and atypical mitoses. Adjuvant chemotherapy was started with mitotane, cisplatin, etoposide and doxorubicin. She experienced severe gastrointestinal side effects and symptomatic adrenal insufficiency, which occurred despite physiological-dose corticosteroid replacement. She also developed hypothyroidism that responded to treatment with levothyroxine and peripheral precocious puberty (PPP) with progressive breast development and rapidly advancing bone age. Five months after discontinuing mitotane, her adrenal insufficiency persisted and she developed secondary central precocious puberty (CPP). This case demonstrates the diverse endocrine complications associated with mitotane therapy, which contrast with the presentation of ACC itself. It also provides the first evidence that the known estrogenic effect of mitotane can manifest as PPP. Learning points: Adrenocortical carcinoma is an important differential diagnosis for virilization in young children Mitotane is a chemotherapeutic agent that is used to treat adrenocortical carcinoma and causes adrenal necrosis Mitotane is an endocrine disruptor. In addition to the intended effect of adrenal insufficiency, it can cause hypothyroidism, with gynecomastia also reported in adults. Patients taking mitotane require very high doses of hydrocortisone replacement therapy because mitotane interferes with steroid metabolism. This effect persists after mitotane therapy is completed In our case, mitotane caused peripheral precocious puberty, possibly through its estrogenic effect.Keywords
This publication has 10 references indexed in Scilit:
- Causes, diagnosis, and treatment of central precocious pubertyThe Lancet Diabetes & Endocrinology, 2016
- Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidismClinical Endocrinology, 2015
- Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5α-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen ReplacementThe Journal of Clinical Endocrinology & Metabolism, 2013
- Systemic Treatment of Adrenocortical Carcinoma in Children: Data from the German GPOH-MET 97 TrialKlinische Padiatrie, 2012
- Therapeutic Concentrations of Mitotane (o,p′-DDD) Inhibit Thyrotroph Cell Viability and TSH Expression and Secretion in a Mouse Cell Line ModelEndocrinology, 2010
- Clinical management of adrenocortical carcinomaBest Practice & Research Clinical Endocrinology & Metabolism, 2009
- Adjuvant Mitotane Treatment for Adrenocortical CarcinomaNew England Journal of Medicine, 2007
- Mitotane Has an Estrogenic Effect on Sex Hormone-Binding Globulin and Corticosteroid-Binding Globulin in HumansThe Journal of Clinical Endocrinology & Metabolism, 2006
- Childhood adrenocortical tumoursEuropean Journal of Cancer, 2004
- Mitotane increases the blood levels of hormone-binding proteinsEuropean Journal of Endocrinology, 1991